<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1312223006
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2022
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SODIUM PHENYLACETATE AND SODIUM BENZOATE INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        SODIUM PHENYLACETATE,SODIUM BENZOATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10,10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        11070.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="University of Iowa Pharmaceuticals" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            University of Iowa Pharmaceuticals
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 461]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            QOMEL MEDICAL DRUG STORE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Navinta LLC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A16AX
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
            <div class="p-20 text-center font-20">
                <div class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</div>
            </div>
    </div>
    <div id="A-div" class="box-data">
            <div class="p-20 text-center font-20">
                <span class="p-10 bg-red"><i class="fa fa-times-circle"></i>&nbsp;&#x644;&#x645; &#x64A;&#x62A;&#x645; &#x625;&#x62F;&#x62E;&#x627;&#x644; &#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A;  &#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x644;&#x647;&#x630;&#x627; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621; &#x62D;&#x62A;&#x649; &#x627;&#x644;&#x622;&#x646;</span>
            </div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each mL of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% contains 100 mg of sodium phenylacetate and 100 mg of sodium benzoate, and Water for Injection. Sodium hydroxide and/or hydrochloric acid may have been used for pH adjustment. 
Each vial contains up to 30.504 mg/mL of sodium (see section 4.4) 
 
Excipients with known effect 
Each vial contains 84.7467 mg/mL of Benzoic Acid which is equivalent to 100mg/mL of Sodium Benzoate. 
For the full list of excipients see section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Injection: 10% per 10% sterile, concentrated, aqueous solution of sodium phenylacetate and sodium benzoate. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Posology</p><p dir="ltr">&nbsp;</p><p dir="ltr">Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% must be diluted with sterile 10%</p><p dir="ltr">Dextrose Injection (D10W) before administration. The dilution and dosage of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% are determined by weight for neonates, infants and young children, and by body surface area for larger patients, including older children, adolescents, and adults (Table 1).</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>Table 1: Dosage and Administration</strong></p><p dir="ltr"><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" dir="ltr" style="width:590px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Patient</strong> <strong>Population</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Components of Infusion</strong> <strong>Solution</strong></p><p>Sodium Phenylacetate and</p><p>Sodium Benzoate Injection must be diluted with sterile 10%</p><p>Dextrose Injection at <strong>&ge; </strong>25 mL/Kg before administration<strong>.</strong></p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p><p><strong>Dosage Provided</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sodium</p><p>Phenylacetate and Sodium Benzoate</p><p>Injection 10% / 10%</p></td><td style="vertical-align:top"><p>Arginine HCl</p><p>Injection,</p><p>10%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Sodium</p><p>Phenylacetate</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Sodium</p><p>Benzoate</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Arginine HCl</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>CPS and OTC Deficiency</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_22074"
   o:spid="_x0000_s1029" style='width:9.85pt;height:92.25pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1252,11717" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
">
   <v:rect id="Rectangle_x0020_224" o:spid="_x0000_s1030" style='position:absolute;
    left:-1191;top:8860;width:4048;height:1666;rotation:-5898239fd;
    visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDXEZ7JxQAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pa8JA
FMTvhX6H5Qm91Y1BbIlughRKelGoVvH4zL78wezbNLtq/PZuoeBxmJnfMItsMK24UO8aywom4wgE
cWF1w5WCn+3n6zsI55E1tpZJwY0cZOnz0wITba/8TZeNr0SAsEtQQe19l0jpipoMurHtiINX2t6g
D7KvpO7xGuCmlXEUzaTBhsNCjR191FScNmejYDfZnve5Wx/5UP6+TVc+X5dVrtTLaFjOQXga/CP8
3/7SCuJ4Cn9nwhGQ6R0AAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQDXEZ7JxQAAANwAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'>Patie</b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><v:rect id="Rectangle_x0020_225" o:spid="_x0000_s1031" style='position:absolute;
    left:314;top:7333;width:1037;height:1666;rotation:-5898239fd;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'>n</b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><v:rect id="Rectangle_x0020_226" o:spid="_x0000_s1032" style='position:absolute;
    left:173;top:6414;width:1320;height:1666;rotation:-5898239fd;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBIj6UlxQAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pa8JA
FMTvhX6H5Qne6sYgWlI3QQolXhSqVXp8zb78odm3aXbV+O3dguBxmJnfMMtsMK04U+8aywqmkwgE
cWF1w5WCr/3HyysI55E1tpZJwZUcZOnz0xITbS/8Seedr0SAsEtQQe19l0jpipoMuontiINX2t6g
D7KvpO7xEuCmlXEUzaXBhsNCjR2911T87k5GwWG6Px1zt/3h7/JvMdv4fFtWuVLj0bB6A+Fp8I/w
vb3WCuJ4Dv9nwhGQ6Q0AAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBIj6UlxQAAANwAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'>ts</b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><v:rect id="Rectangle_x0020_227" o:spid="_x0000_s1033" style='position:absolute;
    left:600;top:5836;width:466;height:1666;rotation:-5898239fd;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'><span
       style='mso-spacerun:yes'> </span></b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><v:rect id="Rectangle_x0020_17674" o:spid="_x0000_s1034" style='position:absolute;
    left:119;top:5020;width:2926;height:1666;rotation:-5898239fd;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'>0</b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><v:rect id="Rectangle_x0020_17675" o:spid="_x0000_s1035" style='position:absolute;
    left:-985;top:3916;width:2925;height:1665;rotation:-5898239fd;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'><span
       style='mso-spacerun:yes'> </span>to</b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><v:rect id="Rectangle_x0020_229" o:spid="_x0000_s1036" style='position:absolute;
    left:600;top:3291;width:466;height:1666;rotation:-5898239fd;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'><span
       style='mso-spacerun:yes'> </span></b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><v:rect id="Rectangle_x0020_17668" o:spid="_x0000_s1037" style='position:absolute;
    left:-158;top:2199;width:2331;height:1666;rotation:-5898239fd;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'>20</b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><v:rect id="Rectangle_x0020_17669" o:spid="_x0000_s1038" style='position:absolute;
    left:-1034;top:1323;width:2331;height:1666;rotation:-5898239fd;
    visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'><span
       style='mso-spacerun:yes'> </span></b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><v:rect id="Rectangle_x0020_231" o:spid="_x0000_s1039" style='position:absolute;
    left:315;top:918;width:1036;height:1666;rotation:-5898239fd;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'>k</b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><v:rect id="Rectangle_x0020_232" o:spid="_x0000_s1040" style='position:absolute;
    left:367;top:209;width:932;height:1666;rotation:-5898239fd;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'>g</b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><v:rect id="Rectangle_x0020_233" o:spid="_x0000_s1041" style='position:absolute;
    left:522;top:-336;width:621;height:1666;rotation:-5898239fd;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'>:</b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><v:rect id="Rectangle_x0020_234" o:spid="_x0000_s1042" style='position:absolute;
    left:600;top:-715;width:465;height:1666;rotation:-5898239fd;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'><span
       style='mso-spacerun:yes'> </span></b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="35" height="127" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
   id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
   path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1026" type="#_x0000_t75" style='width:9.85pt;height:92.25pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p><p>Loading:</p><p>over 90 to&nbsp; 120 minutes Maintenance:&nbsp; over 24 hours</p></td><td><p>2.5 mL/kg</p></td><td><p>2 mL/kg</p></td><td><p>250 mg/kg</p></td><td><p>250 mg/kg</p></td><td><p>200 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>ASS and ASL Deficiency</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dose</strong></p><p>Loading:</p><p>over 90 to&nbsp; 120 minutes Maintenance:&nbsp; over 24 hours</p></td><td><p>2.5 mL/kg</p></td><td><p>6 mL/kg</p></td><td><p>250 mg/kg</p></td><td><p>250 mg/kg</p></td><td><p>600 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>CPS and OTC Deficiency</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:bottom"><p><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_22646"
   o:spid="_x0000_s1026" style='width:9.85pt;height:68.9pt;
   mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
   coordsize="1252,8747" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
   <v:rect id="Rectangle_x0020_376" o:spid="_x0000_s1027" style='position:absolute;
    left:-4757;top:2324;width:11180;height:1666;rotation:-5898239fd;
    visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAt3YWlxgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pa8JA
FMTvBb/D8oTe6sa2GIluggglvVRQW+nxNfvyB7Nv0+yq6bd3C4LHYWZ+wyyzwbTiTL1rLCuYTiIQ
xIXVDVcKPvdvT3MQziNrbC2Tgj9ykKWjhyUm2l54S+edr0SAsEtQQe19l0jpipoMuontiINX2t6g
D7KvpO7xEuCmlc9RNJMGGw4LNXa0rqk47k5Gwdd0fzrkbvPD3+Vv/Prh801Z5Uo9jofVAoSnwd/D
t/a7VvASz+D/TDgCMr0CAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAA
CwAAAAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEALd2FpcYAAADcAAAA
DwAAAAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPoCAAAAAA==
" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'>Patient&gt;20kg:</b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><v:rect id="Rectangle_x0020_377" o:spid="_x0000_s1028" style='position:absolute;
    left:600;top:-715;width:465;height:1666;rotation:-5898239fd;visibility:visible;
    mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
    <v:textbox inset="0,0,0,0">
     <![if !mso]>
     <table cellpadding=0 cellspacing=0 width="100%">
      <tr>
       <td><![endif]>
       <div>
       <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
       8.0pt;margin-left:0in;text-indent:0in;line-height:107%'><b
       style='mso-bidi-font-weight:normal'><span
       style='mso-spacerun:yes'> </span></b><o:p></o:p></p>
       </div>
       <![if !mso]></td>
      </tr>
     </table>
     <![endif]></v:textbox>
   </v:rect><w:wrap type="none"/>
   <w:anchorlock/>
  </v:group><![endif]--><img width="20" height="120" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
   id="_x0000_i1025" type="#_x0000_t75" style='width:9.85pt;height:68.9pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span><![endif]--></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p><p>Loading:</p><p>over 90 to&nbsp; 120 minutes Maintenance:&nbsp; over 24 hours</p></td><td><p>55 mL/m<sup>2</sup></p></td><td><p>2 mL/kg</p></td><td><p>5.5g/m<sup>2</sup></p></td><td><p>5.5 g/m<sup>2</sup></p></td><td><p>200 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>ASS and ASL Deficiency</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Dose</strong></p><p>Loading:</p><p>over 90 to&nbsp; 120 minutes&nbsp;</p><p>Maintenance:</p><p>over 24 hours</p></td><td><p>55 mL/m<sup>2</sup></p></td><td><p>6 mL/kg</p></td><td><p>5.5 g/m<sup>2</sup></p></td><td><p>5.5 g/m<sup>2</sup></p></td><td><p>600 mg/kg</p></td></tr></tbody></table><p dir="ltr">Abbreviations: CPS - carbamyl phosphate synthetase; OTC - ornithine transcarbamylase; ASS - argininosuccinate synthetase; ASL - argininosuccinate lyase</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Special populations </u>&nbsp;</em></p><p dir="ltr"><em>&nbsp;</em></p><p dir="ltr">Pediatric Use&nbsp;</p><p dir="ltr">Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% has been used as a treatment for acute hyperammonemia in pediatric patients including patients in the early neonatal period [Posology and method of administration 4.2].&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Geriatric Use&nbsp;</p><p dir="ltr">Clinical studies of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% did not include any patients aged 65 and over to determine whether they respond differently from younger patients. Urea cycle disorders are presently diseases of the pediatric and younger adult populations. No pharmacokinetic studies of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% have been performed in geriatric patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy in this patient population.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Gender&nbsp;</p><p dir="ltr">Pharmacokinetic parameters of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% were compared in healthy males and females. Bioavailability of both benzoate and phenylacetate was slightly higher in females than in males. However, conclusions cannot be drawn due to the limited number of subjects in this study.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Hepatic Insufficiency&nbsp;</p><p dir="ltr">Limited information is available on the metabolism and excretion of sodium phenylacetate and sodium benzoate in patients with impaired hepatic function. However, metabolic conjugation of sodium phenylacetate and sodium benzoate is known to take place in the liver and kidney. Therefore, caution should be used in administering Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% to patients with hepatic insufficiency.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Renal Impairment&nbsp;</p><p dir="ltr">The drug metabolites of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%</p><p dir="ltr">(phenylacetylglutamine and hippurate) and subsequently ammonia are primarily excreted by the kidney. Therefore, use caution and closely monitor patients with impaired renal function who receive Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Method of administration</p><p dir="ltr">&nbsp;</p><p dir="ltr">Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% is a concentrated solution and must be diluted before intravenous administration via a central venous catheter. Administration through a peripheral intravenous catheter may cause burns. Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% may not be administered by any other route.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% should be administered as a loading dose infusion over 90 to 120 minutes, followed by the same dose repeated as a maintenance infusion administered over 24 hours. Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% should not be administered. Maintenance infusions may be continued until elevated plasma ammonia levels have been normalized or the patient can tolerate oral nutrition and medications. An antiemetic may be administered during Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% infusion to aid control of infusion-associated nausea and vomiting. Administration of analogous oral drugs, such as sodium phenylbutyrate, should be terminated prior to Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% infusion.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% infusion should be started as soon as the diagnosis of hyperammonemia is made. Treatment of hyperammonemia also requires caloric supplementation and restriction of dietary protein. Non-protein calories should be supplied principally as glucose (8&ndash;10 mg/kg/min) with an intravenous fat emulsion added. Attempts should be made to maintain a caloric intake of greater than 80 kcal/kg/day. During and after infusion of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%, ongoing monitoring of the following clinical laboratory values is crucial: plasma ammonia, glutamine, quantitative plasma amino acids, blood glucose, electrolytes, venous or arterial blood gases, AST and ALT. On-going monitoring of the following clinical responses is also crucial to assess patient response to treatment: neurological status, Glasgow Coma Scale, tachypnea, CT or MRI scan or fundoscopic evidence of cerebral edema, and/or of gray matter and white matter damage. Hemodialysis should be considered in patients with severe hyperammonemia or who are not responsive to Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% administration [see Warnings and Precautions 4.4]. In the non-neonatal study patient population treated with Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%, dialysis was required in 13% of hyperammonemic episodes. Standard hemodialysis was the most frequently used dialysis method. High levels of ammonia can be reduced quickly when Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% is used with hemodialysis, as the ammonia-scavenging of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% suppresses the production of ammonia from catabolism of endogenous protein and hemodialysis eliminates the ammonia and ammonia conjugates.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% solutions are physically and chemically stable for up to 24 hours at room temperature and room lighting conditions. No compatibility information is presently available for Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% infusion solutions except for Arginine HCl Injection, 10%, which may be mixed in the same container as Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%. Other infusion solutions and drug products should not be administered together with Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% infusion solution. Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% solutions may be prepared in glass and PVC containers.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Arginine Administration&nbsp;</p><p dir="ltr">Intravenous arginine is an essential component of therapy for patients with carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS), or argininosuccinate lyase (ASL) deficiency. Because hyperchloremic acidosis may develop after highdose arginine hydrochloride administration, chloride and bicarbonate levels should be monitored and appropriate amounts of bicarbonate administered.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">In hyperammonemic infants with suspected, but unconfirmed urea cycle disorders, intravenous arginine should be given (6 mL/kg of Arginine HCl Injection 10%, over 90 minutes followed by the same dose given as a maintenance infusion over 24 hours). If deficiencies of ASS or ASL are excluded as diagnostic possibilities, the intravenous dose of arginine HCl should be reduced to 2 mL/kg/day Arginine HCl Injection 10%.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Converting to Oral Treatment&nbsp;</p><p dir="ltr">Once elevated ammonia levels have been reduced to the normal range, oral therapy, such as sodium phenylbutyrate, dietary management and maintenance protein restrictions should be started or reinitiated.<strong> </strong></p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Decreased Potassium Levels &nbsp;</p><p dir="ltr">Because urine potassium loss is enhanced by the excretion of the non-reabsorbable anions, phenylacetylglutamine and hippurate, plasma potassium levels should be carefully monitored and appropriate treatment given when necessary.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Conditions Associated with Fluid Overload &nbsp;</p><p dir="ltr">Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% contains 30.5 mg of sodium per mL of undiluted product. Thus, Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% should be used with great care, if at all, in patients with congestive heart failure or severe renal insufficiency, and in clinical states in which there is sodium retention with edema. Discontinue administration of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%, evaluate the patient, and institute appropriate therapeutic countermeasures if an adverse event occurs.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Extravasation &nbsp;</p><p dir="ltr">Administration must be through a central venous catheter. Administration through a peripheral line may cause burns. Bolus infusion flow rates are relatively high, especially for infants [Posology and method of administration 4.2]. Extravasation of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% into the perivenous tissues may lead to skin necrosis. If extravasation is suspected, discontinue the infusion and resume at a different infusion site, if necessary. The infusion site must be monitored closely for possible infiltration during drug administration. Do not administer undiluted product.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Neurotoxicity of Phenylacetate &nbsp;</p><p dir="ltr">Because of prolonged plasma levels achieved by phenylacetate in pharmacokinetic studies, repeat loading doses of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% should not be administered. Additionally, neurotoxicity was reported in cancer patients receiving intravenous phenylacetate, 250&ndash;300 mg/kg/day for 14 days, repeated at 4-week intervals. Manifestations were predominantly somnolence, fatigue, and lightheadedness, with less frequent headaches, dysgeusia, hypoacusis, disorientation, impaired memory, and exacerbation of a pre-existing neuropathy. The acute onset of symptoms upon initiation of treatment and reversibility of symptoms when the phenylacetate was discontinued suggest a drug effect. [see Animal Toxicology and/or Pharmacology 5.3]<em>&nbsp; </em></p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr">Hyperventilation and Metabolic Acidosis &nbsp;</p><p dir="ltr">Due to structural similarities between phenylacetate and benzoate to salicylate, Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% may cause side effects typically associated with salicylate overdose, such as hyperventilation and metabolic acidosis. Monitoring of blood chemistry profiles, blood pH and pCO<sub>2</sub> should be performed.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Effect of Benzoic acid</p><p dir="ltr">Sodium Phenylacetate and Sodium Benzoate injection contains Benzoic acid which may increase jaundice (yellowing of the skin and eyes) in newborn babies (up to 4 weeks old).</p><p dir="ltr">&nbsp;</p><p dir="ltr">Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% contains up to 30.504 mg/mL sodium per vial, equivalent to 1.525% of the WHO recommended maximum daily intake for sodium.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Formal drug interaction studies have not been performed with Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Some antibiotics such as penicillin may compete with phenylacetylglutamine and hippurate for active secretion by renal tubules, which may affect the overall disposition of the infused drug.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Probenecid is known to inhibit the renal transport of many organic compounds, including aminohippuric acid, and may affect renal excretion of phenylacetylglutamine and hippurate.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">There have been reports that valproic acid can induce hyperammonemia through inhibition of the synthesis of <em>N</em>-acetylglutamate, a co-factor for carbamyl phosphate synthetase. Therefore, administration of valproic acid to patients with urea cycle disorders may exacerbate their condition and antagonize the efficacy of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Pregnancy</u></p><p dir="ltr">&nbsp;</p><p dir="ltr">Pregnancy Category C</p><p dir="ltr">&nbsp;</p><p dir="ltr">Risk Summary &nbsp;</p><p dir="ltr">Available data with Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4%, and 15 to 20%, respectively.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Breastfeeding Risk Summary&nbsp;</p><p dir="ltr">There are no data on the presence of sodium phenylacetate, sodium benzoate in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% and any potential adverse effects on the breastfed infant from Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% or from the underlying maternal condition.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Fertility</p><p dir="ltr">Studies to evaluate the possible impairment of fertility or mutagenic potential of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% have not been performed. Results indicate that sodium benzoate is not mutagenic or carcinogenic, and does not impair fertility.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No studies on the effects on the ability to drive and use machines have been performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">a. Summary of the safety profile</p><p dir="ltr">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">The safety data were obtained from 316 patients who received Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% as emergency (rescue) or prospective treatment for hyperammonemia as part of an uncontrolled, open-label study. The study population included patients between the ages of 0 to 53 years with a mean (SD) of 6.2 (8.54) years; 51% were male and 49% were female who had the following diagnoses: OTC (46%), ASS (22%), CPS (12%), ASL (2%), ARG (&lt; 1%), THN (&lt; 1%), and other (18%).&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">b. Tabulated summary of adverse reactions</p><p dir="ltr">Adverse reactions profiles differed by age group. Patients &le; 30 days of age had more blood and lymphatic system disorders and vascular disorders (specifically hypotension), while patients &gt; 30 days of age had more gastrointestinal disorders (specifically nausea, vomiting and diarrhea).&nbsp;</p><p dir="ltr">Less common adverse reactions (&lt; 3% of patients) that are characterized as severe are listed below by body system.&nbsp;</p><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr" style="width:630px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA system organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions </strong></p></td></tr><tr><td style="vertical-align:top"><p>BLOOD AND LYMPHATIC SYSTEM DISORDERS</p></td><td style="vertical-align:top"><p>coagulopathy, pancytopenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>CARDIAC DISORDERS</p></td><td style="vertical-align:top"><p>atrial rupture, bradycardia, cardiac or cardiopulmonary arrest/failure, cardiogenic shock, cardiomyopathy, pericardial effusion&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>EYE DISORDERS</p></td><td style="vertical-align:top"><p>blindness</p></td></tr><tr><td style="vertical-align:top"><p>GASTROINTESTINAL DISORDERS</p></td><td style="vertical-align:top"><p>abdominal distension, gastrointestinal hemorrhage</p></td></tr><tr><td style="vertical-align:top"><p>GENERAL DISORDERS AND</p><p>ADMINISTRATION-SITE CONDITIONS</p></td><td style="vertical-align:top"><p>asthenia, brain death, chest pain, multiorgan failure, edema&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>HEPATOBILIARY DISORDERS</p></td><td style="vertical-align:top"><p>cholestasis, hepatic artery stenosis, hepatic failure/hepatotoxicity, jaundice&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>INFECTIONS AND INFESTATIONS</p></td><td style="vertical-align:top"><p>sepsis/septic shock</p></td></tr><tr><td style="vertical-align:top"><p>INJURY, POISONING AND PROCEDURAL COMPLICATIONS</p></td><td style="vertical-align:top"><p>brain herniation, subdural hematoma, overdose&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>INVESTIGATIONS</p></td><td style="vertical-align:top"><p>blood carbon dioxide changes, blood glucose changes, blood pH increased, cardiac output decreased, pCO2 changes, respiratory rate increased</p></td></tr><tr><td style="vertical-align:top"><p>METABOLISM AND NUTRITION DISORDERS</p></td><td style="vertical-align:top"><p>alkalosis, dehydration, fluid overload/retention, hypoglycemia, hyperkalemia, hypernatremia, alkalosis, tetany&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED</p></td><td style="vertical-align:top"><p>hemangioma acquired&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>NERVOUS SYSTEM DISORDERS</p></td><td style="vertical-align:top"><p>areflexia, ataxia, brain infarction, brain hemorrhage, cerebral atrophy, clonus, depressed level of consciousness, encephalopathy, nerve paralysis, intracranial pressure increased, subdural hematoma, tremor&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>PSYCHIATRIC DISORDERS</p></td><td style="vertical-align:top"><p>acute psychosis, aggression, confusional state, hallucinations&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>RENAL AND URINARY DISORDERS</p></td><td style="vertical-align:top"><p>anuria, renal failure, urinary retention&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS</p></td><td style="vertical-align:top"><p>acute respiratory distress syndrome, dyspnea, hypercapnia, hyperventilation, Kussmaul respiration, pneumonia aspiration, pneumothorax, pulmonary hemorrhage, pulmonary edema, respiratory acidosis or alkalosis, respiratory arrest/failure&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>SKIN AND SUBCUTANEOUS TISSUE DISORDERS</p></td><td style="vertical-align:top"><p>alopecia, blister, pruritis generalized, rash, urticaria&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>VASCULAR DISORDERS</p></td><td style="vertical-align:top"><p>flushing, hemorrhage, hypertension, phlebothrombosis/thrombosis</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">c. <u>Description of selected adverse reactions</u></p><p dir="ltr">Adverse reactions were reported with similar frequency in patients with OTC, ASS, CPS, and diagnoses categorized as &ldquo;other.&rdquo; Nervous system disorders were more frequent in patients with OTC and CPS, compared with patients with ASS and patients with &ldquo;other&rdquo; diagnoses. Convulsions and mental impairment were reported in patients with OTC and CPS. These observations are consistent with literature reports that patients with enzyme deficiencies occurring earlier in the urea cycle (i.e., OTC and CPS) tend to be more severely affected.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Table 2: Adverse Reactions Occurring in &ge; 3% of Patients Treated with Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%</p><p dir="ltr">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" dir="ltr" style="width:619px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Patients N=316</p></td></tr><tr><td style="vertical-align:top"><p>Number of patients with any adverse event</p></td><td style="vertical-align:top"><p>163 (52%)</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>35 (11%)</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>12 (4%)</p></td></tr><tr><td style="vertical-align:top"><p>Disseminated intravascular coagulation</p></td><td style="vertical-align:top"><p>11 (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>28 (9%)</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>42 (13%)</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>10 (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>9 (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>29 (9%)</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration-site conditions</p></td><td style="vertical-align:top"><p>45 (14%)</p></td></tr><tr><td style="vertical-align:top"><p>Injection-site reaction</p></td><td style="vertical-align:top"><p>11 (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>17 (5%)</p></td></tr><tr><td style="vertical-align:top"><p>Infections</p></td><td style="vertical-align:top"><p>39 (12%)</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top"><p>9 (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>12 (4%)</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>32 (10%)</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>67 (21%)</p></td></tr><tr><td style="vertical-align:top"><p>Acidosis</p></td><td style="vertical-align:top"><p>8 (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Hyperammonemia</p></td><td style="vertical-align:top"><p>17 (5%)</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycemia</p></td><td style="vertical-align:top"><p>22 (7%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcemia</p></td><td style="vertical-align:top"><p>8 (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalemia</p></td><td style="vertical-align:top"><p>23 (7%)</p></td></tr><tr><td style="vertical-align:top"><p>Metabolic acidosis</p></td><td style="vertical-align:top"><p>13 (4%)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>71 (22%)</p></td></tr><tr><td style="vertical-align:top"><p>Brain edema</p></td><td style="vertical-align:top"><p>17 (5%)</p></td></tr><tr><td style="vertical-align:top"><p>Coma</p></td><td style="vertical-align:top"><p>10 (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Convulsions</p></td><td style="vertical-align:top"><p>19 (6%)</p></td></tr><tr><td style="vertical-align:top"><p>Mental impairment</p></td><td style="vertical-align:top"><p>18 (6%)</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>16 (5%)</p></td></tr><tr><td style="vertical-align:top"><p>Agitation</p></td><td style="vertical-align:top"><p>8 (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>14 (4%)</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>47 (15%)</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory distress</p></td><td style="vertical-align:top"><p>9 (3%)</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>19 (6%)</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>19 (6%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>14 (4%)</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p><p dir="ltr">d. Pediatric Population</p><p dir="ltr">Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% has been used as a treatment for acute hyperammonemia in pediatric patients including patients in the early neonatal period [Posology and method of administration 4.2].&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">e. Other special population(s) <em>Geriatric Use&nbsp; </em></p><p dir="ltr">Clinical studies of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% did not include any patients aged 65 and over to determine whether they respond differently from younger patients. Urea cycle disorders are presently diseases of the pediatric and younger adult populations. No pharmacokinetic studies of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% have been performed in geriatric patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant disease or other drug therapy in this patient population.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Gender&nbsp;</p><p dir="ltr">Pharmacokinetic parameters of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% were compared in healthy males and females. Bioavailability of both benzoate and phenylacetate was slightly higher in females than in males. However, conclusions cannot be drawn due to the limited number of subjects in this study.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Hepatic Insufficiency&nbsp;</p><p dir="ltr">Limited information is available on the metabolism and excretion of sodium phenylacetate and sodium benzoate in patients with impaired hepatic function. However, metabolic conjugation of sodium phenylacetate and sodium benzoate is known to take place in the liver and kidney. Therefore, caution should be used in administering Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% to patients with hepatic insufficiency.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Renal Impairment&nbsp;</p><p dir="ltr">The drug metabolites of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%</p><p dir="ltr">(phenylacetylglutamine and hippurate) and subsequently ammonia are primarily excreted by the kidney. Therefore, use caution and closely monitor patients with impaired renal function who receive Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%.</p><p dir="ltr"><strong>&nbsp;</strong></p><p dir="ltr"><strong>To report any side effect(s):&nbsp; </strong></p><p dir="ltr">Saudi Arabia</p><p dir="ltr">&bull;&nbsp; The National Pharmacovigilance Centre (NPC)</p><p dir="ltr">&bull;&nbsp; &bull;SFDA Call Center: 19999</p><p dir="ltr">&bull;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p dir="ltr">&bull;&nbsp; Website: https://ade.sfda.gov.sa/</p><p dir="ltr">Other GCC states /other countries</p><p dir="ltr">-Please contact the relevant competent authority</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Overdosage has been reported during Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% treatment in urea cycle-deficient patients. All patients in the uncontrolled open-label study were to be treated with the same dose of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%. However, some patients received more than the dose level specified in the protocol. In 16 of the 64 deaths, the patient received a known overdose of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%. Causes of death in these patients included cardiorespiratory failure/arrest (6 patients), hyperammonemia (3 patients), increased intracranial pressure (2 patients), pneumonitis with septic shock and coagulopathy (1 patient), error in dialysis procedure (1 patient), respiratory failure (1 patient), intractable hypotension and probable sepsis (1 patient), and unknown (1 patient). Additionally, other signs of intoxication may include obtundation (in the absence of hyperammonemia), hyperventilation, a severe compensated metabolic acidosis, perhaps with a respiratory component, large anion gap, hypernatremia and hyperosmolarity, progressive encephalopathy, cardiovascular collapse, and death.&nbsp; In case of overdose of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%, discontinue the drug and institute appropriate emergency medical monitoring and procedures. In severe cases, the latter may include hemodialysis (procedure of choice) or peritoneal dialysis (when hemodialysis is unavailable).&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Various alimentary tract and metabolism products, ATC code: A16AX30</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pharmacodynamics</p><p dir="ltr">In patients with hyperammonemia due to deficiencies in enzymes of the urea cycle, Sodium</p><p dir="ltr">Phenylacetate and Sodium Benzoate Injection 10% / 10% has been shown to decrease elevated plasma ammonia levels. These effects are considered to be the result of reduction in nitrogen overload through glutamine and glycine scavenging by Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% in combination with appropriate dietary and other supportive measures.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Mechanism of action</p><p dir="ltr">Urea cycle disorders can result from decreased activity of any of the following enzymes: <em>N</em>acetylglutamate synthetase (NAGS), carbamyl phosphate synthetase (CPS), argininosuccinate synthetase (ASS), ornithine transcarbamylase (OTC), argininosuccinate lyase (ASL), or arginase (ARG).&nbsp;</p><p dir="ltr">Sodium phenylacetate and sodium benzoate are metabolically active compounds that can serve as alternatives to urea for the excretion of waste nitrogen. Figure 1 is a schematic illustrating how the components of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%, phenylacetate and benzoate, provide an alternative pathway for nitrogen disposal in patients without a fully functioning urea cycle. Phenylacetate conjugates with glutamine in the liver and kidneys to form phenylacetylglutamine, via acetylation. Phenylacetylglutamine is excreted by the kidneys via glomerular filtration and tubular secretion. The nitrogen content of phenylacetylglutamine per mole is identical to that of urea (both contain two moles of nitrogen). Two moles of nitrogen are removed per mole of phenylacetate when it is conjugated with glutamine. Similarly, preceded by acylation, benzoate conjugates with glycine to form hippuric acid, which is rapidly excreted by the kidneys by glomerular filtration and tubular secretion. One mole of hippuric acid contains one mole of waste nitrogen. Thus, one mole of nitrogen is removed per mole of benzoate when it is conjugated with glycine.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Figure 1</p><p dir="ltr">&nbsp;</p><p dir="ltr"><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1907" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:433pt;height:301.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="577" height="402" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CPS &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; = carbamyl phosphate synthetase;&nbsp;</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OTC&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; = ornithine transcarbamylase;&nbsp;</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ASS&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; = argininosuccinate synthetase;&nbsp;</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ASL &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; = argininosuccinate lyase;</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ARG&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; = arginase;</p><p dir="ltr">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NAGS&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; = <em>N</em>-acetylglutamate synthetase</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The pharmacokinetics of intravenously administered Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% was characterized in healthy adult volunteers. Both benzoate and phenylacetate exhibited nonlinear kinetics. Following 90 minute intravenous infusion mean AUC<sub>last</sub> for benzoate was</p><p dir="ltr">20.3, 114.9, 564.6, 562.8, and 1599.1 mcg/mL following doses of 1, 2, 3.75, 4, and 5.5 g/m<sup>2</sup>, respectively. The total clearance decreased from 5.19 to 3.62 L/h/m<sup>2 </sup>at the 3.75 and 5.5 g/m<sup>2 </sup>doses, respectively.&nbsp;</p><p dir="ltr">Similarly, phenylacetate exhibited nonlinear kinetics following the priming dose regimens. AUC<sub>last</sub> was 175.6, 713.8, 2040.6, 2181.6, and 3829.2 mcg<!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_23165" o:spid="_x0000_i1026" type="#_x0000_t75"
 style='width:1.5pt;height:1.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="2" height="2" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />h/mL following doses of 1, 2, 3.75, 4, and 5.5 g/m<sup>2</sup>, respectively. The total clearance decreased from 1.82 to 0.89 mcg<!--[if gte vml 1]><v:shape
 id="Picture_x0020_23166" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:1.5pt;
 height:1.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
</v:shape><![endif]--><img width="2" height="2" src="file:///C:/Users/kfqw175/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />h/mL with increasing dose (3.75 and 4 g/m<sup>2</sup>, respectively).&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">During the sequence of 90 minute priming infusion followed by a 24-hour maintenance infusion, phenylacetate was detected in the plasma at the end of infusion (T<sub>max</sub> of 2 hr at 3.75 g/m<sup>2</sup>) whereas, benzoate concentrations declined rapidly (T<sub>max</sub> of 1.5 hr at 3.75 g/m<sup>2</sup>) and were undetectable at 14 and 26 hours following the 3.75 and 4 g/m<sup>2 </sup>dose, respectively.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">A difference in the metabolic rates for phenylacetate and benzoate was noted. The formation of hippurate from benzoate occurred more rapidly than that of phenylacetylglutamine from phenylacetate, and the rate of elimination for hippurate appeared to be more rapid than that for phenylacetylglutamine.&nbsp; Pharmacokinetic observations have also been reported from twelve episodes of hyperammonemic encephalopathy in seven children diagnosed (age 3 to 26 months) with urea cycle disorders who had been administered Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% intravenously. These data showed peak plasma levels of phenylacetate and benzoate at approximately the same times as were observed in healthy adults. As in healthy adults, the plasma levels of phenylacetate were higher than benzoate and were present for a longer time.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">The pharmacokinetics of intravenous phenylacetate have been reported following administration to adult patients with advanced solid tumors. The decline in serum phenylacetate concentrations following a loading infusion of 150 mg/kg was consistent with saturable enzyme kinetics. Ninety-nine percent of administered phenylacetate was excreted as phenylacetylglutamine.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Carcinogenesis, Mutagenesis, Impairment of Fertility<strong> </strong><strong>&nbsp;</strong></p><p dir="ltr">Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10%. Studies to evaluate the possible impairment of fertility or mutagenic potential of Sodium Phenylacetate and Sodium Benzoate Injection 10% / 10% have not been performed. Results indicate that sodium benzoate is not mutagenic or carcinogenic, and does not impair fertility.&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr">Animal Toxicology and/or Pharmacology &nbsp;</p><p dir="ltr">In animal studies, subcutaneous administration to rat pups of 190&ndash;474 mg/kg of phenylacetate caused decreased proliferation and increased loss of neurons, and reduced central nervous system (CNS) myelin. Cerebral synapse maturation was retarded, and the number of functioning nerve terminals in the cerebrum was reduced, which resulted in impaired brain growth. Pregnant rats were given phenylacetate at 3.5 &mu;mol/g/day subcutaneously from gestation day 7 through normal delivery. Prenatal exposure of rat pups to phenylacetate produced lesions in layer 5 cortical pyramidal cells; dendritic spines were longer and thinner than normal and reduced in number.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Sodium hydroxide, NF</p><p dir="ltr">Hydrochloric acid, NF</p><p dir="ltr">Sterile water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store at 25&deg;C (77&deg;F), excursions permitted to 15&deg; to 30&deg;C (59&deg; to 86&deg;F).&nbsp; Keep out of reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Sodium phenylacetate and sodium benzoate Injection, 10% / 10%, is supplied in a sterile, nonpyrogenic, single use Type I glass vials closed with rubber stopper and sealed with white aluminium flip-off seal.</p><p dir="ltr">Each single dose vial contains 50 mL sodium Phenylacetate and Sodium Benzoate Injection 10% /10%.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Pack size: one vial in one carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Navinta LLC, 
1499 Lower Ferry Road, 
Ewing, NJ-08618-1414, USA 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2021. 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>